The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE

OBJECTIVE: Sorafenib have been shown to be effective in the treatment of advanced HCC and has been standard therapy since its release in Japan in 2009 (Llovet et al., 2008; Cheng et al., 2009). However, due to a low response rate, more aggressive combination treatment has been utilized as a multimod...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, Yusuke, Kaneko, Rena, Yano, Yuichiro, Kamada, Kentaro, Ikehara, Takashi, Nagai, Hidenari, Sato, Yuzuru, Igarashi, Yoshinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568902/
https://www.ncbi.nlm.nih.gov/pubmed/32592380
http://dx.doi.org/10.31557/APJCP.2020.21.6.1797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568902/
https://www.ncbi.nlm.nih.gov/pubmed/32592380
http://dx.doi.org/10.31557/APJCP.2020.21.6.1797

Ejemplares similares